Spyre Therapeutics, Inc.

SYRENASDAQ

Market cap7.99B USDAs of Sep 22, 2026

Healthcare· Biotechnology· US

$92.03

Session change unavailable

Market closed · NASDAQ

Status checked Oct 25, 2026, 1:27 AM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

Spyre Therapeutics, Inc. (SYRE)

Loading market observation…

Spyre Therapeutics, Inc. (SYRE) stock forecast and scoring

Review the dated model forecast and five-factor Scorecard for SYRE. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.

12M forecast summary

Forecast unavailable for this stock and horizon.

The estimate uses its dated starting price. It does not predict returns from today’s quote.

View forecast details, dates and available ranges

Stock scorecard

Loading research…

Company Overview

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Similar Stocks

Research snapshot

Loading research…

Spyre Therapeutics, Inc. research

Loading research…

Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.

Company Overview

Similar Stocks

Explore related companies in our coverage. Open a stock for its full forecast and Scorecard.

Intellia Therapeutics, Inc.

NTLA

Same industryBiotechnology

Latest observed price

$12.22

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$14.70

+20.3%

From $12.22 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

Vertex Pharmaceuticals Incorporated

VRTX

Same industryBiotechnology

Latest observed price

$510.72

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$546.06

+6.9%

From $510.72 starting price

Target Sep 21, 2027

Overall Score

Strong

Forecast basis Sep 21, 2026

Score date Sep 22, 2026

View stock

Regeneron Pharmaceuticals, Inc.

REGN

Same industryBiotechnology

Latest observed price

$798.17

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$853.89

+7.0%

From $798.17 starting price

Target Sep 21, 2027

Overall Score

Strong

Forecast basis Sep 21, 2026

Score date Sep 22, 2026

View stock

Revolution Medicines, Inc.

RVMD

Same industryBiotechnology

Latest observed price

$192.76

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$218.24

+13.2%

From $192.76 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.

Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc. (SYRE) stock forecast and scoring

12M forecast summary

Stock scorecard

Company Overview

Similar Stocks

Research snapshot

Spyre Therapeutics, Inc. research

Spyre Therapeutics, Inc. (SYRE) stock forecast and scoring

12M forecast summary

Scoring · Spyre Therapeutics, Inc. (SYRE) stock scorecard

Scoring Breakdown

Growth

Value

Quality

Safety

Momentum

Stock scorecard

Company Overview